In recent years there have been various discoveries connecting inflammation and lung cancer and clearly there is growing interest in this area of cancer research. The link between unresolved inflammation and cancer has been well established with estimates that 15% of cancer deaths are inflammation‐related. Evidence for this link includes the following: a) some inflammatory diseases are associated with increased risk of cancer development; b) inflammatory mediators are present surrounding and within most tumors; c) overexpression of inflammatory cytokines increases cancer development and progression in murine studies; d) inhibition of inflammatory mediators decreases cancer development and progression; and e) the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) has been found to decrease cancer incidence and delay progression. The volume will present aspects of the inflammatory tumor microenvironment (TME), its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of micro‐RNAs (miRNAs) and an increase in a stem cell phenotype. The book will also cover the mechanisms of inflammatory mediators. Chronic overexpression of inflammatory mediators in the TME, as seen in smokers and patients with non‐small cell lung cancer (NSCLC), can also lead to increased tumor initiation, progression, invasion and metastasis. The volume will provide a comprehensive perspective of the latest findings and summaries of progress made regarding inflammation and its connection to lung cancer.

This volume examines in detail the role of chronic inflammatory processes in the development of several types of cancer. Leading experts describe the latest results of molecular and cellular research on infection, cancer-related inflammation and tumorigenesis. Further, the clinical significance of these findings in preventing cancer progression and approaches to treating the diseases are discussed. Individual chapters cover cancer of the lung, colon, breast, brain, head and neck, pancreas, prostate, bladder, kidney, liver, cervix and skin as well as gastric cancer, sarcoma, lymphoma, leukemia and multiple myeloma.

This second edition volume expands on the previous edition with an update on the broad spectrum of research models, techniques, and protocols used in laboratories by basic and clinical researchers. The chapters in this book are divided into two parts. Part One discusses the latest findings on the development and characterization of representative research models for chronic immune-based diseases and inflammation-associated cancers. Part Two covers biochemical, molecular, and cellular biological techniques that are commonly used to dissect the molecular mechanisms and cellular processes that drive the pathogenesis of certain disease states. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Inflammation and Cancer: Methods and Protocols, Second Edition is a valuable resource for those with a diverse range of laboratory-based experience, ranging from novice undergraduate students to established basic or clinical researchers who wish to diversify their existing portfolio of practical knowledge in the field.

Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models. The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development. - Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases - Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases - Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology)

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

An overview of the current systems biology-based knowledge and the experimental approaches for deciphering the biological basis of cancer.

Smoking responsible for 90% of cancer deaths. Incidence of lung cancer is rising. Lung cancer is responsible for more cancer deaths than colorectal cancer, breast cancer, and prostate cancer combined. Lung cancer primarily strikes people over age 45. By the time that an individual develops symptoms, spread has usually occurred. Lung cancer is directly related to smoking. Over 40 carcinogens have been identified in cigarette smoke. The risk of developing lung cancer is directly related to the number of cigarettes smoked. The change in consumption from unfiltered high tar cigarettes to filtered low tar cigarettes parallels the change in incidence from squamous cell carcinoma to adenocarcinoma. There is a long interval between quitting smoking and elimination of lung cancer risk. Up to 40% of newly diagnosed lung cancer occurs in former smokers. (median abstinence duration 9 years). This book presents the latest research in the field from around the world.